Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay...

Celý popis

Podrobná bibliografia

Vydané v:	Cancers Ročník 12; číslo 6; s. 1449
Hlavní autori:	Mollica, Veronica, Rizzo, Alessandro, Montironi, Rodolfo, Cheng, Liang, Giunchi, Francesca, Schiavina, Riccardo, Santoni, Matteo, Fiorentino, Michelangelo, Lopez-Beltran, Antonio, Brunocilla, Eugenio, Brandi, Giovanni, Massari, Francesco
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI 02.06.2020
Predmet:	Review urothelial carcinoma immunotherapy PD-L1 antibody drug conjugates clinical trials immune checkpoint inhibitors FGFR PD-1
ISSN:	2072-6694, 2072-6694
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!